Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Optimalisering av oppbevaring, varighet og seponeringsstrategier for farmakoterapi for opioidbruksforstyrrelser (RDD)

9. november 2026 oppdatert av: NYU Langone Health

NIDA-CTN-0100: Optimalisering av oppbevaring, varighet og seponeringsstrategier for farmakoterapi for opioidbruksforstyrrelser (RDD)

This is a two phase study investigating combinations of pharmacological and behavioral interventions to optimize the treatment of Opioid Use Disorder (OUD). The Retention Phase will assess strategies for improving retention on buprenorphine (BUP) and extended-release injectable naltrexone (XR-NTX). The Discontinuation Phase will assess which approaches are most likely to lead to long-term success (absence of relapse), and what characteristics of participants distinguish those who can safely discontinue Medications for Opioid Use Disorder (MOUD) from those who remain at risk of relapse and should not discontinue.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The main objectives of this study are:

  1. To test strategies to improve retention in treatment on medications for opioid use disorder (MOUD), among patients initiating treatment for OUD.
  2. To test strategies to improve outcomes among patients who have achieved stable remission on MOUD and want to discontinue MOUD.
  3. To develop models to predict who is able to discontinue MOUD without relapse, based on patient characteristics, including duration of MOUD prior to discontinuation.

The study will have a multicenter, randomized, pragmatic non-blinded design. The study has two phases, a Retention Phase and a Discontinuation Phase.

Studietype

Intervensjonell

Registrering (Faktiske)

1516

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • University of Arkansas for Medical Sciences (UAMS) / Center for Addiction Services and Treatment (CAST)
    • California
      • Tarzana, California, Forente stater, 91356
        • Tarzana Treatment Centers, Inc.
    • Connecticut
      • Bridgeport, Connecticut, Forente stater, 06610
        • Liberation Programs, Inc.
    • Florida
      • Clearwater, Florida, Forente stater, 33760
        • Operation PAR
      • Jacksonville, Florida, Forente stater, 32204
        • Gateway Community Services
      • Orlando, Florida, Forente stater, 32806
        • Aspire Health Partners
    • Maryland
      • Baltimore, Maryland, Forente stater, 21229
        • Mountain Manor / Maryland Treatment Centers
    • Massachusetts
      • Belmont, Massachusetts, Forente stater, 02478
        • McLean Hospital
      • Fall River, Massachusetts, Forente stater, 02720
        • Stanley Street Treatment and Resources, Inc.
      • Newton, Massachusetts, Forente stater, 02458
        • Square Medical Group, LLC
    • Missouri
      • Cape Girardeau, Missouri, Forente stater, 63703
        • Gibson Center for Behavioral Change
    • New Hampshire
      • Lebanon, New Hampshire, Forente stater, 03766
        • Dartmouth Hitchcock - ATP
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87106
        • University of New Mexico Addiction and Substance Abuse Program
    • New York
      • New York, New York, Forente stater, 10016
        • Bellevue Hospital Center
    • Oregon
      • Roseburg, Oregon, Forente stater, 97470
        • Adapt Integrated Health Care
      • Winston, Oregon, Forente stater, 97496
        • Adapt Integrated Health Care
    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forente stater, 15213
        • Center for Psychiatric and Chemical Dependency Services (CPCDS)
      • Pittsburgh, Pennsylvania, Forente stater, 15219
        • Internal Medicine Recovery Engagement Program (IM-REP)
    • South Carolina
      • Conway, South Carolina, Forente stater, 29526
        • Shoreline Behavioral Health Services
    • Utah
      • Salt Lake City, Utah, Forente stater, 84108
        • Huntsman Mental Health Institute / University of Utah
    • West Virginia
      • Morgantown, West Virginia, Forente stater, 26505
        • Chestnut Ridge Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria for Retention Phase:

  1. 18 years of age or older;
  2. Meet DSM-5 criteria for current opioid use disorder (heroin, fentanyl or other synthetic opioids, and/or prescription opioids);
  3. Seeking treatment for opioid use disorder and choosing either buprenorphine (BUP) or extended-release injection naltrexone (XR-NTX);
  4. If choosing buprenorphine, willing to be randomized to SL-BUP-16mg, SL-BUP-32mg, or XR-BUP;
  5. Willing to be randomized to either MM (standard Medical Management plus counseling treatment as usual available at the site) or MMR (MM plus usual counseling and access to an app delivering CM + CBT);
  6. In good-enough general health (meaning good enough health to be in outpatient treatment) as determined by the study medical clinician on the basis of medical history, review of systems, and physical/mental status exam, to permit treatment with XR-NTX or BUP;
  7. Willing and able to provide written informed consent;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control for the duration of participation in the study (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Retention Phase:

  1. Serious medical, psychiatric, or co-occurring substance use disorder or concomitant medication that, in the opinion of the study medical clinician, makes the patient not appropriate for outpatient treatment with buprenorphine or XR-NTX, but instead requires a higher or different level of care. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
    3. Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. Known allergy or sensitivity to preferred medication or its components;

  4. Maintenance on methadone at the time of signing consent;

  5. For those preferring XR-NTX, presence of pain of sufficient severity as to require ongoing pain management with opioids;

  6. For those preferring XR-NTX, body habitus that, in the judgment of the study physician, precludes safe intramuscular injection of XR-NTX (e.g., BMI>40, excess fat tissue over the buttocks, emaciation);

  7. If female, currently pregnant or breastfeeding or planning on conception;

  8. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  9. Have used the reSET-O or CHESS Connections mHealth apps in the 3 months prior to consent;

  10. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area).

Inclusion Criteria for Discontinuation Phase:

  1. 18 years of age or older;
  2. Have been receiving buprenorphine for OUD for at least the past year or XR-NTX pharmacotherapy for OUD for at least the past 6 months prior to consent for the Discontinuation Phase;
  3. Express the desire to discontinue MOUD after a shared decision-making discussion with the treating provider;
  4. Meet stability criteria, i.e., have abstained from opioids (other than buprenorphine), cocaine, methamphetamine, and non-prescribed benzodiazepines for the past ≥12 weeks, and do not meet DSM-5 criteria for current (≥12 weeks) alcohol use disorder (participants with cannabis use will be eligible);
  5. If currently taking buprenorphine, are willing to take either SL-BUP or XR-BUP if randomized to that condition;
  6. Willing to be randomized to either MM or to MMD;
  7. Able to provide written informed consent after discussion with their provider regarding the risks of discontinuation;
  8. Able to speak English sufficiently to understand the study procedures;
  9. If female of childbearing potential, willing to practice an effective method of birth control while in the study and taking study medication (participants who become pregnant during the study will continue to be followed; treatment may be modified consistent with pregnancy).

Exclusion Criteria for Discontinuation Phase:

  1. Serious medical or psychiatric disorder or concomitant medication that, in the opinion of the study medical clinician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include:

    1. Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
    2. Severe, untreated, or inadequately treated psychiatric condition (e.g., active psychosis, uncontrolled bipolar disorder) as assessed by history and/or clinical interview, requiring a different level of care (e.g., hospitalization);
  2. Suicidal or homicidal ideation or behavior requiring a different level of care (e.g., hospitalization);

  3. For participants entering the study taking buprenorphine, presence of pain requiring or likely requiring ongoing pain management with buprenorphine or other opioids;

  4. If female, currently pregnant or breastfeeding or planning on conception;

  5. Use of opioids (other than buprenorphine), cocaine, methamphetamine, or non-prescribed benzodiazepines in the past 12 weeks;

  6. Meets current DSM-5 criteria for any current alcohol use disorder;

  7. Are currently in jail, prison or other overnight facility as required by court of law or have pending legal action that could prevent participation in study activities;

  8. Have used the Connections mHealth app in the 3 months prior to consent (other than Connections in the Retention Phase);

  9. Other major reasons that might prevent an individual from participating in the study (e.g., a planned move out of the area.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Faktoriell oppgave
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Retention: SL-BUP standard dose + MM

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MM consists of standard Medical Management and the usual counseling at the treatment program.

Eksperimentell: Retention: SL-BUP high dose + MM

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MM consists of standard Medical Management and the usual counseling at the treatment program.

Eksperimentell: Retention: XR-BUP + MM

Extended-release injectable buprenorphine (XR-BUP) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi
Eksperimentell: Retention: XR-NTX + MM

Extended-release injectable naltrexone (XR-NTX) plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Andre navn:
  • Vivitrol
  • naltrekson med forlenget frigivelse
Eksperimentell: Retention: SL-BUP standard dose + MMR

Standard dose sublingual buprenorphine-naloxone (SL-BUP) 16mg/day target plus MMR, consisting of Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Retention: SL-BUP high dose + MMR

High dose sublingual buprenorphine-naloxone (SL-BUP) 32mg/day target plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Retention: XR-BUP + MMR

Extended-release injectable buprenorphine (XR-BUP) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Retention: XR-NTX + MMR

Extended-release injectable naltrexone (XR-NTX) plus MMR, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Andre navn:
  • Vivitrol
  • naltrekson med forlenget frigivelse

MMR consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Discontinuation: Discontinue SL-BUP with SL-BUP + MM

Start on SL-BUP, taper with SL-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MM consists of standard Medical Management and the usual counseling at the treatment program.

Eksperimentell: Discontinuation: Discontinue SL-BUP with XR-BUP + MM

Start on SL-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi
Eksperimentell: Discontinuation: Discontinue XR-BUP with XR-BUP + MM

Start on XR-BUP, taper with XR-BUP, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi
Eksperimentell: Discontinuation: Discontinue XR-NTX with XR-NTX + MM

Start on XR-NTX, taper with XR-NTX, plus MM, consisting of standard Medical Management and usual counseling at the treatment program.

MM consists of standard Medical Management and the usual counseling at the treatment program.

Monthly dosing of extended-release injectable naltrexone

Andre navn:
  • Vivitrol
  • naltrekson med forlenget frigivelse
Eksperimentell: Discontinuation: Discontinue SL-BUP with SL-BUP + MMD

Start on SL-BUP, taper with SL-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Daily dosing of sublingual buprenorphine-naloxone

Andre navn:
  • Suboxone
  • sublingualt buprenorfin

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Discontinuation: Discontinue SL-BUP with XR-BUP + MMD

Start on SL-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Discontinuation: Discontinue XR-BUP with XR-BUP + MMD

Start on XR-BUP, taper with XR-BUP, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Weekly/monthly dosing of extended-release injectable buprenorphine

Andre navn:
  • CAM2038
  • buprenorfin med forlenget frigivelse
  • Brixadi

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Eksperimentell: Discontinuation: Discontinue XR-NTX with XR-NTX + MMD

Start on XR-NTX, taper with XR-NTX, plus MMD, consisting of standard Medical Management and usual counseling, plus a technology-based behavioral component.

Monthly dosing of extended-release injectable naltrexone

Andre navn:
  • Vivitrol
  • naltrekson med forlenget frigivelse

MMD consists of Medical Management and usual counseling, plus a technology-based behavioral component.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Retention: Continuous retention in MOUD treatment through 26 weeks
Tidsramme: Retention: from randomization through week 26

Binary (yes/no). Continuously enrolled in maintenance treatment on one or more of the evidence-based MOUD modalities (e.g., SL-BUP, XR-BUP, XR-NTX, or methadone maintenance) with no more than a 28-day gap on MOUD over the 26-week period.

Retention: from randomization through week 26
Discontinuation: Completed Discontinuation without Relapse
Tidsramme: Discontinuation: from randomization through week 24 follow up

Binary (yes/no). Discontinuing MOUD during the taper period, no return to MOUD, and no relapse to opioid use, either during the taper (up to 48 weeks for those entering on BUP or 24 weeks for those entering on XR-NTX) or during the 24 weeks after MOUD is discontinued.

Discontinuation: from randomization through week 24 follow up

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Retention KS1: Weekly opioid abstinence
Tidsramme: Retention: from randomization through week 26

Weekly opioid abstinence (measured by Timeline Followback, not contradicted by toxicology test). Repeated yes/no measure for each of weeks 1 through 26.

Retention: from randomization through week 26
Retention KS2: Treatment effectiveness
Tidsramme: Retention: at week 26

Retention treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 26.

Retention: at week 26
Retention KS3: Treatment by baseline severity
Tidsramme: Retention: at week 26

Treatment by baseline severity interaction where severity is indicated by the randomization stratum injection use (yes/no).

Retention: at week 26
Discontinuation KS1: Completed Discontinuation
Tidsramme: Discontinuation: from randomization through week 24 follow up

Completed Discontinuation without regard to relapse status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS2: Relapse
Tidsramme: Discontinuation: from randomization through week 24 follow up

Relapse - separate binary outcome without regard to discontinuation status

Discontinuation: from randomization through week 24 follow up
Discontinuation KS3: Safety
Tidsramme: Discontinuation: from randomization through week 24 follow up

Safety outcomes (binary, any one or more occurrences): overdoses, all non-fatal plus fatal.

Discontinuation: from randomization through week 24 follow up
Discontinuation KS4: Treatment effectiveness
Tidsramme: Discontinuation: at end of taper (EoT) and week 24 follow up

Discontinuation treatment effectiveness, measured by the Treatment Effectiveness Assessment (TEA, Ling et. al, 2012); a brief instrument to assess patient progress in treatment and recovery along 4 domains (substance use, health, lifestyle and community) at week 24. Measured at the end of taper (EOT): up to 24 weeks for tapers with XR-NTX and up to 48 weeks for tapers with BUP; and at the week 24 follow up (primary outcome timepoint).

Discontinuation: at end of taper (EoT) and week 24 follow up

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Edward V Nunes, MD, New York State Psychiatric Institute/Columbia University Irving Medical Center
  • Hovedetterforsker: Roger Weiss, MD, Harvard Medical School/McLean Hospital
  • Hovedetterforsker: John Rotrosen, MD, NYU Langone Health

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. juni 2021

Primær fullføring (Antatt)

31. desember 2026

Studiet fullført (Antatt)

31. januar 2027

Datoer for studieregistrering

Først innsendt

29. juni 2020

Først innsendt som oppfylte QC-kriteriene

6. juli 2020

Først lagt ut (Faktiske)

9. juli 2020

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

10. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

9. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 19-01363
  • UG1DA015831 (U.S. NIH-stipend/kontrakt)
  • CTN-0100 (Annen identifikator: NIDA Clinical Trials Network)
  • UG1DA013035 (U.S. NIH-stipend/kontrakt)
  • 20-PRS-057 (Annen identifikator: Biomedical Research Alliance of New York (BRANY) sIRB)
  • 146193 (Annen identifikator: FDA/IND#)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

This study will comply with the NIH Data Sharing Policy and Implementation Guidance (https://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm) and (for HEAL-funded studies) the HEAL Public Access and Data Sharing Policy (https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/research/heal-public-access-data-sharing-policy).

Primary data for this study will be available to the public in the NIDA data repository. For more details on data sharing please visit https://datashare.nida.nih.gov/.

The primary outcome(s) publication will be included along with study underlying primary data in the data share repository, and it will also be deposited in PubMed Central http://www.pubmedcentral.nih.gov/ per NIH Policy (http://publicaccess.nih.gov/).

IPD-delingstidsramme

Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .